Glenmede Trust’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.4M Sell
167,483
-6,923
-4% -$571K 0.07% 259
2025
Q4
$14.9M Buy
+174,406
New +$14.3M 0.07% 238
2025
Q1
$16.1M Sell
222,551
-126,499
-36% -$9.05M 0.09% 222
2024
Q4
$25.8M Sell
349,050
-32,118
-8% -$2.25M 0.13% 143
2024
Q3
$25.2M Buy
381,168
+21,505
+6% +$1.56M 0.12% 167
2024
Q2
$33.2M Sell
359,663
-883
-0.2% -$78.2K 0.17% 118
2024
Q1
$34.5M Buy
360,546
+1,194
+0.3% +$100K 0.17% 126
2023
Q4
$27.4M Sell
359,352
-1,338
-0.4% -$93.1K 0.14% 150
2023
Q3
$25M Sell
360,690
-797
-0.2% -$64K 0.14% 154
2023
Q2
$29.9M Hold
361,487
0.17% 135
2023
Q1
$29.9M Sell
361,487
-7,638
-2% -$600K 0.17% 135
2022
Q4
$27.5M Sell
369,125
-133,351
-27% -$10.3M 0.16% 147
2022
Q3
$41.5M Buy
502,476
+3,229
+0.6% +$311K 0.26% 101
2022
Q2
$47.5M Buy
499,247
+132,316
+36% +$13.7M 0.28% 91
2022
Q1
$43.2M Sell
366,931
-731
-0.2% -$82K 0.21% 116
2021
Q4
$47.6M Sell
367,662
-919
-0.2% -$107K 0.23% 108
2021
Q3
$41.7M Sell
368,581
-9,651
-3% -$1.1M 0.22% 115
2021
Q2
$39.2M Sell
378,232
-9,244
-2% -$871K 0.2% 125
2021
Q1
$32.4M Sell
387,476
-2,607
-0.7% -$220K 0.17% 142
2020
Q4
$35.6M Sell
390,083
-2,019
-0.5% -$167K 0.2% 123
2020
Q3
$31.3M Buy
392,102
+2,359
+0.6% +$184K 0.19% 134
2020
Q2
$26.9M Sell
389,743
-7,922
-2% -$563K 0.16% 141
2020
Q1
$30.9M Hold
397,665
0.14% 199
2019
Q4
$30.9M Buy
397,665
+14,331
+4% +$1.12M 0.14% 199
2019
Q3
$28.1K Sell
383,334
-55,092
-13% -$3.87M 0.13% 217
2019
Q2
$27K Buy
438,426
+11,358
+3% +$687K 0.12% 249
2019
Q1
$27.2K Sell
427,068
-918,174
-68% -$52.4M 0.12% 252
2018
Q4
$68.7K Buy
1,345,242
+904,491
+205% +$45.8M 0.34% 73
2018
Q3
$25.6M Sell
440,751
-12,126
-3% -$593K 0.1% 286
2018
Q2
$22M Buy
452,877
+22,446
+5% +$1.05M 0.1% 287
2018
Q1
$16.2M Hold
430,431
0.07% 325
2017
Q4
$16.2M Buy
430,431
+1,845
+0.4% +$67.7K 0.07% 325
2017
Q3
$15.6M Buy
428,586
+120
+0% +$4.58K 0.07% 324
2017
Q2
$13.4M Hold
428,466
0.06% 332
2017
Q1
$13.4M Buy
428,466
+21,282
+5% +$666K 0.06% 332
2016
Q4
$12.7M Buy
407,184
+338,820
+496% +$11M 0.07% 337
2016
Q3
$2.75M Sell
68,364
-17,481
-20% -$658K 0.02% 563
2016
Q2
$2.85M Buy
85,845
+15,828
+23% +$542K 0.02% 547
2016
Q1
$2.06M Sell
70,017
-229,146
-77% -$6.32M 0.01% 608
2015
Q4
$7.87M Sell
299,163
-551,079
-65% -$14.3M 0.05% 362
2015
Q3
$20.1M Sell
850,242
-123,984
-13% -$2.99M 0.15% 236
2015
Q2
$23.1M Sell
974,226
-363,702
-27% -$8.21M 0.17% 209
2015
Q1
$31.8M Buy
1,337,928
+489,270
+58% +$11M 0.23% 122
2014
Q4
$18M Buy
848,658
+44,916
+6% +$902K 0.14% 229
2014
Q3
$13.7M Buy
803,742
+790,842
+6,131% +$12.5M 0.12% 252
2014
Q2
$184K Hold
12,900
﹤0.01% 1201
2014
Q1
$159K Hold
12,900
﹤0.01% 1254
2013
Q4
$140K Sell
12,900
-84
-0.6% -$947 ﹤0.01% 1273
2013
Q3
$150K Buy
12,984
+84
+0.7% +$983 ﹤0.01% 1236
2013
Q2
$143K Buy
+12,900
New +$153K ﹤0.01% 1200

Other funds holding EW

Glenmede Trust's EW Position: Q1 2026 in Review

Glenmede Trust reduced its Edwards Lifesciences (EW) stake by 4% in Q1 2026, selling an estimated $571K and leaving 167,483 shares worth $13.4M. The position accounts for 0.07% of the portfolio, ranked #259.

Glenmede Trust first reported a position in EW in Q2 2013 and has held it in 50 quarters since. The position peaked at $47.6M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Glenmede Trust held 167,483 shares of Edwards Lifesciences worth $13.4M as of Q1 2026.
  • Glenmede Trust sold 6,923 Edwards Lifesciences shares in Q1 2026, an estimated $571K.
  • Edwards Lifesciences made up 0.07% of Glenmede Trust's portfolio in Q1 2026, its #259 holding.
  • Glenmede Trust first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 50 quarters since.
  • Glenmede Trust's Edwards Lifesciences position peaked at $47.6M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.